{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:10:50Z","timestamp":1793034650558,"version":"4.5.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Despite the effectiveness of existing anti\u2013vascular endothelial growth factor (VEGF) therapies, a need remains for further treatment options to improve response rates and\/or reduce injection or monitoring frequency in patients with diabetic macular edema (DME).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy and safety of brolucizumab vs aflibercept dosed every 4 weeks in participants with DME.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Participants, and Setting<\/jats:title><jats:p>This 52-week, double-masked, phase 3 randomized clinical trial included treatment-naive adults and adults who had previously received anti-VEGF therapy. Data were collected from September 2019 to March 2020, and data were analyzed from April 2020 to February 2021.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Brolucizumab, 6 mg, intravitreal injection every 4 weeks or aflibercept, 2 mg, intravitreal injection every 4 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Participants were randomized 2:1 to brolucizumab, 6 mg, or aflibercept, 2 mg. The primary end point was change from baseline in best-corrected visual acuity at week 52. Secondary end points were the proportion of participants with a 2-step improvement or greater from baseline in Diabetic Retinopathy Severity Scale score, the proportion of eyes with absence of both subretinal fluid and intraretinal fluid, change from baseline in central subfield thickness, and safety at week 52.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 517 participants were randomized to brolucizumab (n\u2009=\u2009346) or aflibercept (n\u2009=\u2009171); 299 (57.8%) were male, and the mean (SD) age was 60.7 (10.2) years. Brolucizumab was noninferior to aflibercept in best-corrected visual acuity (Early Treatment Diabetic Retinopathy Study letter score) change from baseline at week 52 (brolucizumab, 12.2-letter improvement; aflibercept, 11.0-letter improvement; difference, 1.1; 95% CI, \u22120.6 to 2.9; noninferiority margin, 4; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). Brolucizumab was superior to aflibercept for the proportion of eyes without subretinal and intraretinal fluid (brolucizumab, 144 of 346 [41.6%]; aflibercept, 38 of 171 [22.2%]; difference, 20.0%; 95% CI, 12.5to 28.6; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) and mean central subfield thickness change from baseline at week 52 (brolucizumab, \u2212237.8 \u03bcm; aflibercept, \u2212196.5 \u03bcm; difference, \u221241.4; 95% CI, \u221258.9 to \u221223.8; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). Incidence of intraocular inflammation was 4.0% (14 of 346) in the brolucizumab arm and 2.9% (5 of 171) in the aflibercept arm, incidence of retinal vasculitis was 0.9% (3 of 346) and 0.6% (1 of 171), respectively, and incidence of retinal vascular occlusion was 0.3% (1 of 346) and 0.6% (1 of 171). One participant in the brolucizumab arm had retinal artery occlusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In these study participants with DME, no clinically meaningful differences in visual outcomes were noted between the brolucizumab and aflibercept arms; some superior anatomic improvements were noted in the brolucizumab arm. No new safety concerns were identified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03917472\">NCT03917472<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2023.5248","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T16:01:33Z","timestamp":1700150493000},"page":"1152","source":"Crossref","is-referenced-by-count":45,"title":["Efficacy and Safety of Brolucizumab for Diabetic Macular Edema"],"prefix":"10.1001","volume":"141","author":[{"given":"Rishi P.","family":"Singh","sequence":"first","affiliation":[{"name":"Cleveland Clinic Martin Hospitals, Cleveland Clinic Florida, Stuart"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Barakat","sequence":"additional","affiliation":[{"name":"Retinal Consultants of Arizona, Phoenix"},{"name":"University of Arizona College of Medicine, Phoenix"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Ip","sequence":"additional","affiliation":[{"name":"Doheny Eye Institute, UCLA Department of Ophthalmology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Bellaire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Eichenbaum","sequence":"additional","affiliation":[{"name":"Retina Vitreous Associates of Florida, St Petersburg"},{"name":"Morsani College of Medicine, University of South Florida, Tampa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunir","family":"Joshi","sequence":"additional","affiliation":[{"name":"Pinnacle Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Warrow","sequence":"additional","affiliation":[{"name":"Cumberland Valley Retina Consultants, Hagerstown, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veeral S.","family":"Sheth","sequence":"additional","affiliation":[{"name":"University Retina and Macula Associates, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Stefanickova","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, Comenius University, Bratislava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Soo","family":"Kim","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanyin","family":"He","sequence":"additional","affiliation":[{"name":"Beijing Novartis Pharma, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga Eun","family":"Cho","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Wang","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Emanuelli","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico"},{"name":"Emanuelli Research and Development Center, Arecibo, Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"eoi230067r1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","article-title":"Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss.","volume":"2","author":"Lee","year":"2015","journal-title":"Eye Vis (Lond)"},{"issue":"11","key":"eoi230067r2","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis.","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"key":"eoi230067r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107840","article-title":"IDF Diabetes Atlas: a review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018.","volume":"157","author":"Thomas","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"eoi230067r4","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1007\/s13300-018-0513-2","article-title":"Intravitreal ranibizumab therapy for diabetic macular edema in routine practice: two-year real-life data from a non-interventional, multicenter study in Germany.","volume":"9","author":"Ziemssen","year":"2018","journal-title":"Diabetes Ther"},{"issue":"11","key":"eoi230067r5","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema.","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi230067r6","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial.","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi230067r7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamaophthalmol.2015.5346","article-title":"Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment.","volume":"134","author":"Bressler","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"eoi230067r8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.oret.2017.10.014","article-title":"Outcomes of diabetic macular edema eyes with limited early response in the VISTA and VIVID studies.","volume":"2","author":"Pieramici","year":"2018","journal-title":"Ophthalmol Retina"},{"issue":"6","key":"eoi230067r9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2016.02.007","article-title":"Visual and anatomic outcomes in patients with diabetic macular edema with limited initial anatomic response to ranibizumab in RIDE and RISE.","volume":"123","author":"Pieramici","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi230067r10","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","article-title":"The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.","volume":"118","author":"Mitchell","year":"2011","journal-title":"Ophthalmology"},{"issue":"9","key":"eoi230067r11","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/j.ophtha.2010.12.034","article-title":"Economic considerations of macular edema therapies.","volume":"118","author":"Smiddy","year":"2011","journal-title":"Ophthalmology"},{"issue":"10","key":"eoi230067r12","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.ophtha.2013.02.019","article-title":"Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study.","volume":"120","author":"Lang","year":"2013","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi230067r13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/bjophthalmol-2013-303352","article-title":"Cost-effectiveness of treatments for diabetic macular oedema: should we pay more attention to the appraisal and reporting of economic evaluations?","volume":"98","author":"Virgili","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"eoi230067r14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/ICU.0000000000000152","article-title":"What have we learnt about the management of diabetic macular edema in the antivascular endothelial growth factor and corticosteroid era?","volume":"26","author":"Agarwal","year":"2015","journal-title":"Curr Opin Ophthalmol"},{"key":"eoi230067r15","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2147\/OPTH","article-title":"Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion.","volume":"10","author":"Sivaprasad","year":"2016","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"eoi230067r16","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1001\/jamaophthalmol.2019.1963","article-title":"Association between change in visual acuity and change in central subfield thickness during treatment of diabetic macular edema in participants randomized to aflibercept, bevacizumab, or ranibizumab: a post hoc analysis of the Protocol T randomized clinical trial.","volume":"137","author":"Bressler","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"eoi230067r17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","article-title":"Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA).","volume":"237","author":"Schmidt-Erfurth","year":"2017","journal-title":"Ophthalmologica"},{"issue":"9","key":"eoi230067r18","doi-asserted-by":"publisher","first-page":"e0256461","DOI":"10.1371\/journal.pone.0256461","article-title":"Effectiveness of anti-vascular endothelial growth factors in neovascular age-related macular degeneration and variables associated with visual acuity outcomes: results from the EAGLE study.","volume":"16","author":"Staurenghi","year":"2021","journal-title":"PLoS One"},{"issue":"8","key":"eoi230067r19","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1016\/j.ophtha.2016.04.004","article-title":"Predictors of diabetic macular edema treatment frequency with ranibizumab during the open-label extension of the RIDE and RISE trials.","volume":"123","author":"Wykoff","year":"2016","journal-title":"Ophthalmology"},{"key":"eoi230067r20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","article-title":"KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema.","volume":"238","author":"Brown","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"eoi230067r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2023.07.012","article-title":"KESTREL and KITE phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema.","author":"Wykoff","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"eoi230067r22","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ophtha.2022.04.028","article-title":"MERLIN: phase 3a, multicenter, randomized, double-masked trial of brolucizumab in participants with neovascular age-related macular degeneration and persistent retinal fluid.","volume":"129","author":"Khanani","year":"2022","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi230067r23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration.","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi230067r24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration.","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi230067r25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1177\/2474126419893829","article-title":"American Society of Retina Specialists Clinical Practice Guidelines on the management of nonproliferative and proliferative diabetic retinopathy without diabetic macular edema.","volume":"4","author":"Yonekawa","year":"2020","journal-title":"J Vitreoretin Dis"},{"issue":"3","key":"eoi230067r26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","article-title":"Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial.","volume":"136","author":"Bressler","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"eoi230067r27","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ophtha.2010.12.033","article-title":"Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.","volume":"118","author":"Elman","year":"2011","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi230067r28","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi230067r29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ophtha.2019.09.025","article-title":"Diabetic Retinopathy Preferred Practice Pattern.","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"issue":"10","key":"eoi230067r30","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.ophtha.2018.04.007","article-title":"Guidelines on diabetic eye care: the International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings.","volume":"125","author":"Wong","year":"2018","journal-title":"Ophthalmology"},{"key":"eoi230067r31","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5639284","article-title":"Optical coherence tomography parameters related to vision impairment in patients with diabetic macular edema: a quantitative correlation analysis.","volume":"2020","author":"Li","year":"2020","journal-title":"J Ophthalmol"},{"issue":"3","key":"eoi230067r32","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41433-019-0522-z","article-title":"Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: a post hoc analysis of Protocol I data.","volume":"34","author":"Sadda","year":"2020","journal-title":"Eye (Lond)"},{"issue":"10326","key":"eoi230067r33","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"eoi230067r34","author":"Lanzetta"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2811933\/jamaophthalmology_singh_2023_oi_230067_1702489039.39502.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T16:01:55Z","timestamp":1703174515000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2811933"}},"subtitle":["The KINGFISHER Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.5248","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}